Sanofi
SNY
#164
Rank
A$182.01 B
Marketcap
A$74.57
Share price
1.29%
Change (1 day)
3.54%
Change (1 year)

Sanofi is a French pharmaceutical company created in 2004 by the merger of Sanofi-Synthรฉlabo and Aventis. With sales of EUR 36.1 billion in 2019 and more than 100,000 employees worldwide, Sanofi is one of the largest pharmaceutical companies in the world in terms of sales.

P/E ratio for Sanofi (SNY)

P/E ratio as of December 2025 (TTM): 13.3

According to Sanofi's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 13.3201. At the end of 2023 the company had a P/E ratio of 19.7.

P/E ratio history for Sanofi from 2003 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202319.729.56%
202215.2
20178.48-39.15%
201613.9-11.71%
201515.815.13%
201413.7-23.57%
201317.951.39%
201211.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Merck
MRK
13.2-1.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
15.1 13.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
17.6 32.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
18.1 35.63%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
GlaxoSmithKline
GSK
13.4 0.79%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
44.9 237.24%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Johnson & Johnson
JNJ
19.4 45.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
49.0 268.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Novo Nordisk
NVO
13.7 2.91%๐Ÿ‡ฉ๐Ÿ‡ฐ Denmark
Abbott Laboratories
ABT
15.5 16.71%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.